Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2010-06-15
- Last Posted Date
- 2017-12-19
- Lead Sponsor
- Threshold Pharmaceuticals
- Target Recruit Count
- 214
- Registration Number
- NCT01144455
- Locations
- 🇺🇸
Fairfax Northern Virginia Hematology Oncology, PC, Fairfax, Virginia, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Loyola University Medical Center, Maywood, Illinois, United States
Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2008-08-28
- Last Posted Date
- 2015-05-07
- Lead Sponsor
- Threshold Pharmaceuticals
- Target Recruit Count
- 71
- Registration Number
- NCT00743379
- Locations
- 🇺🇸
Mayo Clinic Cancer Center, Scottsdale, Arizona, United States
🇺🇸Indiana University Cancer Center, Indianapolis, Indiana, United States
🇺🇸Premiere Oncology of Arizona, Scottsdale, Arizona, United States
Dose-Escalation Study of TH-302 in Combination With Doxorubicin to Treat Patients With Advanced Soft Tissue Sarcoma
- First Posted Date
- 2008-08-28
- Last Posted Date
- 2017-10-26
- Lead Sponsor
- Threshold Pharmaceuticals
- Target Recruit Count
- 107
- Registration Number
- NCT00742963
- Locations
- 🇺🇸
Sarcoma Oncology Center, Santa Monica, California, United States
🇺🇸Stanford University, Stanford, California, United States
🇺🇸H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors
- First Posted Date
- 2007-07-02
- Last Posted Date
- 2012-07-27
- Lead Sponsor
- Threshold Pharmaceuticals
- Target Recruit Count
- 129
- Registration Number
- NCT00495144
- Locations
- 🇺🇸
Indiana University Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸St. Mary's Medical Center, San Francisco, California, United States
🇺🇸Mayo Clinic Rochester, Rochester, Minnesota, United States
Safety and Efficacy Study of Glufosfamide in Patients With Recurrent Sensitive Small Cell Lung Carcinoma
- Conditions
- First Posted Date
- 2007-02-15
- Last Posted Date
- 2009-04-30
- Lead Sponsor
- Threshold Pharmaceuticals
- Target Recruit Count
- 50
- Registration Number
- NCT00435578
- Locations
- 🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸California Cancer Center, Greenbrae, California, United States
Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia
- Conditions
- First Posted Date
- 2007-02-15
- Last Posted Date
- 2009-04-29
- Lead Sponsor
- Threshold Pharmaceuticals
- Target Recruit Count
- 480
- Registration Number
- NCT00435448
- Locations
- 🇵🇱
Wojewódzki Szpital,Oddział i Poradnia Urologiczna, Legnica, Poland
ðŸ‡ðŸ‡ºDombóvári Szt. Lukács Egészségügyi Közhasznú, Dombóvár, Hungary
ðŸ‡ðŸ‡ºPetz Aladár County Hospital, Gyor, Hungary
Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia
- Conditions
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2009-04-29
- Lead Sponsor
- Threshold Pharmaceuticals
- Target Recruit Count
- 240
- Registration Number
- NCT00237536
- Locations
- 🇺🇸
Stanford University Hospital, Stanford, California, United States
🇺🇸Specialty Care Research, Peoria, Illinois, United States
🇺🇸Werner, Murdock & Francis, PA, Urology Associates, Greenbelt, Maryland, United States
Study of Safety and Efficacy of Glufosfamide in Combination With Gemcitabine in Cancer
- Conditions
- First Posted Date
- 2005-02-02
- Last Posted Date
- 2009-04-30
- Lead Sponsor
- Threshold Pharmaceuticals
- Target Recruit Count
- 47
- Registration Number
- NCT00102752
- Locations
- 🇺🇸
Norton Healthcare Cancer Center, Louisville, Kentucky, United States
🇺🇸Indiana Cancer Center, Indianapolis, Indiana, United States
🇺🇸Arizona Cancer Center, Tucson, Arizona, United States
Study of the Efficacy and Safety of Glufosfamide Compared With Best Supportive Care in Metastatic Pancreatic Cancer
- Conditions
- First Posted Date
- 2004-12-10
- Last Posted Date
- 2009-04-30
- Lead Sponsor
- Threshold Pharmaceuticals
- Target Recruit Count
- 300
- Registration Number
- NCT00099294
- Locations
- 🇲🇽
Centro Medico ISSEMYM, Metepec, Mexico
🇦🇷Hospital Alvarez, Buenos Aires, Argentina
🇷🇺Central Clinical Hospital of the presidentof the Russian Federation, Moscow, Russian Federation
Dose Escalation Trial of 2-Deoxy-D-Glucose (2DG) in Subjects With Advanced Solid Tumors
- Conditions
- First Posted Date
- 2004-11-15
- Last Posted Date
- 2009-04-29
- Lead Sponsor
- Threshold Pharmaceuticals
- Target Recruit Count
- 50
- Registration Number
- NCT00096707
- Locations
- 🇺🇸
University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸Indiana University Cancer Center, Indianapolis, Indiana, United States
🇺🇸Institute for Drug Development Cancer Therapy & Research Center, San Antonio, Texas, United States